Annual Report

The report describes Cantargia's 2023 progress in nadunolimab, including additional efficacy data and CAN10's entry into clinical development. It presents sustainability commitments covering environmental impact, social responsibility, governance, and support for SDGs 3, 5, 8, 9 and 13. Environmental disclosures include 137 travels producing 19 739 kg CO2 and an average 822 kg per employee. The report also records materially lower R&D and total operating costs during the year.